Australia is pretty good at healthcare innovation. We have great clinicians, strong research institutions, digital health businesses tackling real problems, health insurers experimenting with prevention, governments funding pilots and hospitals redesigning models of care.
The ideas are there. What we seem to be much less good at is turning those ideas into something that operates at meaningful scale.
That was one of the strongest themes to come out of my latest Innovation Insider conversation with Joey Colandra, whose career has crossed pharmacy, primary care, consulting, digital health, private health insurance and government. Joey has worked across organisations including AIA, Medibank and the Victorian Department of Health, which gives him an unusual perspective on the same challenges from several different sides of the system.
And despite those very different vantage points, the problems often look surprisingly similar.
Prevention exposes the problem perfectly
The private health insurance industry is talking about prevention more than I can remember, and that makes sense. Insurers have a clear interest in helping members avoid unnecessary hospitalisations, manage chronic conditions earlier and remain healthier for longer.
Programs such as AIA Vitality and Medibank Live Better demonstrate what is possible when behavioural economics, technology and incentives are combined to encourage healthier decisions. Joey described one example from Vitality that had particularly stuck with him, where a member was incentivised to complete a mammogram as part of the program and the screening identified breast cancer that might otherwise have remained undetected.
The incentive didn’t provide the treatment. It changed the behaviour that led to an earlier diagnosis, and that distinction is important. As Joey put it:
“It’s not actually a clinical problem here. It’s a design problem.”
We already know many of the behaviours associated with better health. Eat better, move more, don’t smoke, limit alcohol and participate in appropriate screening. The bigger opportunity is designing healthcare systems, products and experiences that make those healthier choices easier.
For me, this is exactly why Staying Well has become such an important part of the PHI FACTORS™. The opportunity for health insurers is increasingly broader than paying for care once somebody becomes sick, with potentially much greater value in helping members avoid, delay or better manage illness in the first place.

Who pays today for a benefit realised years from now?
Prevention is often a long-term investment operating inside organisations that are measured in much shorter cycles. A health insurer may invest in improving somebody’s health today, but the financial benefit might take years to appear, the avoided hospital admission may never be directly visible, or the member may switch funds before the original insurer sees the return.
That investment still has to compete with initiatives offering clearer and more immediate financial outcomes. Governments face a similar problem, with the benefit of a preventative intervention potentially extending beyond a budget cycle or an election cycle.
That creates a strange tension where almost everybody agrees prevention is valuable while still struggling to make the economics work. Joey’s experience was that programs such as Vitality and Live Better need more than a compelling proposition, because they also require a board and executive team willing to maintain a long-term view while dealing with all the normal commercial pressures of running the organisation.
That makes prevention a leadership challenge as much as an innovation challenge.

7 things we learnt from nib, Bupa, Medibank and Ramsay
Australia’s biggest healthcare players are sending some pretty clear signals about where the market is heading. I pulled together seven of the most important strategic shifts from their latest results, from prevention and AI to new care models, distribution and the growing battle to own more of the healthcare journey.
We’ve designed a system that pays for activity
There is an even bigger issue sitting underneath prevention. Much of healthcare is still designed to fund activity through consultations, tests, procedures, admissions and bed days. As Joey said:
“The system is designed and funded to respond to illness. That’s the way it is right now, rather than to maintain health.”
That creates some uncomfortable incentives. Imagine a new model of care that produces a better patient outcome, reduces a hospital stay and costs the health system less overall.
On the surface, that looks like an obvious success. But the equation becomes more complicated if the organisation being asked to implement it earns revenue from the activity that disappears, if the organisation paying for the intervention isn’t the organisation receiving the financial benefit, or if the savings sit with the Commonwealth while the investment sits with a state.
The same challenge can apply to private health insurers if they stand to benefit from an intervention but cannot fund every part of it within the current regulatory environment. Suddenly, a model that appears better for the patient and the broader system becomes surprisingly difficult to implement.
The patient experiences one healthcare system. The funding system often experiences Commonwealth, state, hospital, primary care, pharmacy, allied health, private health insurance and consumer funding as separate worlds, and that fragmentation matters enormously when we try to scale something new.
Australia is excellent at pilots
One of Joey’s observations will probably resonate with anyone who has spent time working in healthcare innovation:
“We’re kind of good at doing pilots, but nothing scales very well.”
Australia is good at funding research, testing new technology, establishing partnerships and demonstrating that a model works within one hospital, one insurer, one region or one cohort. The trouble starts when the pilot finishes and the system has to decide what happens next.
Who owns it? Who funds the next stage? Who benefits financially? Who implements it? Who governs it? How does it integrate into existing clinical workflows, and what happens when the original funding disappears?
These questions are often treated as issues to solve after a successful pilot has been completed. I think they need to be part of the innovation design from the beginning, because a pilot should test more than whether an intervention works clinically or operationally.
It should also test whether there is a realistic pathway to scale.

The technology is moving faster than the system around it
The technology Joey and I discussed is genuinely exciting. Genomics could enable far more personalised screening and treatment, pharmacogenomics could help clinicians select medicines based on how an individual is likely to respond, and wearables and smartphones are becoming increasingly sophisticated health sensors.
AI can remove administrative work, identify patterns and support clinical decisions, while connected records could create a much more complete view of a person’s health. Yet every technological breakthrough also creates another question around what we actually do with the information once we have it.
A smartwatch identifying an abnormality is useful only if there is a sensible pathway for somebody to act on it. Genomic information creates value only if consumers trust the organisations holding it and clinicians can use it meaningfully, while AI-generated insights improve care only when they fit into the way care is actually delivered. Joey captured the opportunity nicely:
“The tech becomes the enabler, not the destination.”
Healthcare probably doesn’t need another technology strategy disconnected from the model of care around it. The more important question is what healthcare experience we are trying to create, followed by where technology can help enable it.
Public and private need to work together
One of the things I liked most about this conversation was that it avoided reducing the future of healthcare to a public-versus-private debate. Australia benefits from both, with our public system providing universal access while the private system contributes additional capacity, choice and an environment where new models of care can sometimes be tested.
The two systems also depend heavily on each other. The opportunity lies in getting them working towards increasingly common outcomes rather than operating as parallel systems with different incentives.
Imagine public hospitals, private hospitals, GPs, pharmacies, aged care providers and private health insurers becoming more closely aligned around a shared objective of keeping people healthier for longer. That wouldn’t make the complexity disappear, because funding, data, regulation, accountability and clinical responsibility would all still need to be addressed.
But the incentives would at least start pointing in a similar direction.
Joey described some encouraging examples already appearing. The new Royal Melbourne Hospital is being designed with fewer beds because more care is expected to take place outside the hospital, while Outcome Health uses specialist mental health nurses to triage relevant triple zero calls, with many cases able to be supported without dispatching an ambulance.
These are practical examples of redesigning the system around the outcome we actually want.
What does healthcare look like in ten years?
Towards the end of the conversation, I asked Joey what he hoped Australian healthcare might look like a decade from now. His answer wasn’t centred on dramatically bigger hospitals or significantly more technology, but on redesigning how the system works.
He described a future where funding is better aligned, clinicians are rewarded for keeping people healthy, multidisciplinary teams work at the top of their scope and AI removes administrative burden. Genomics, wearables and connected records could allow healthcare to become more predictive, while interventions become increasingly preventative, personalised and participatory.
Public and private healthcare would also operate as more connected parts of the same ecosystem. It is an ambitious vision, but I don’t think the biggest constraint is whether the technology will exist, because much of it already does.
The challenge is whether the system around that technology can evolve quickly enough.
The next innovation challenge is scale
Perhaps the next era of healthcare innovation needs to spend more time thinking about what happens after the pilot works. The questions of who pays, who benefits, who owns the model, how it scales, what existing activity it replaces and which incentives need to change are fundamental to whether a new idea ever becomes part of the broader system.
Those questions are less exciting than launching something new, but they may ultimately determine whether Australian healthcare innovation produces isolated examples of excellence or meaningful system change.
Increasingly, I think that is where the real opportunity lies.
Listen to my full conversation with Joey Colandra on Innovation Insider, where we explore prevention, healthcare funding, digital health, genomics, AI, public-private collaboration and the future of the Australian healthcare system.


